PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Recruiting now · Phase 2/Phase 3

Conditions studied: Metastatic Cervical Cancer, Persistent Cervical Cancer, Recurrent Cervical Cancer

In brief

This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical cancer.

Key facts

Study ID

NCT07472153

Run by

N.N. Alexandrov National Cancer Centre

People needed

120

Starts

2025-07-01

Expected to finish

2033-06-30

Last updated by the study team

2026-05-28

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18-≤75 years.
• Histologically confirmed diagnosis.
• One of the forms of the cervical cancer:
• Metastatic cervical cancer (stage IVB according to FIGO (International Federation of Gynaecology and Obstetrics) 2018);
• Persistent cervical cancer (primary incurability after radical treatment for stages IIB-IVA cervical cancer according to FIGO 2018);
• Reccurent cervical cancer (first recurrence after completed radical treatment for IA-IVB cervical cancer according to FIGO 2018).
• Availability of material for determining PD-L-1 expression for immunotherapy candidates.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• No contraindications to chemotherapy, immunotherapy, or bevacizumab.
• Signed informed consent to participate in the study.

You may not qualify if…

• Presence of another active malignant invasive neoplasm.
• Pregnancy or lactation period.

Where it is running

• N.N. Alexandrov National Caner Centre — Minsk, Lesnoy, Belarus (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.